Business Description
PharmaLundensis AB
NAICS : 325412
SIC : 2834
ISIN : SE0003359710
Compare
Compare
Traded in other countries / regions
PHAL.Sweden IPO Date
2010-07-06Description
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 3.13 | |||||
| Debt-to-EBITDA | -2.09 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 9.9 | |||||
| 3-Year EPS without NRI Growth Rate | 4.3 | |||||
| 3-Year Book Growth Rate | -10.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.45 | |||||
| 9-Day RSI | 47.15 | |||||
| 14-Day RSI | 46.93 | |||||
| 6-1 Month Momentum % | -20 | |||||
| 12-1 Month Momentum % | 46.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | |||||
| Quick Ratio | 0.16 | |||||
| Cash Ratio | 0.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.5 | |||||
| Shareholder Yield % | -3.34 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -178.28 | |||||
| ROA % | -41.71 | |||||
| ROIC % | -36.67 | |||||
| ROC (Joel Greenblatt) % | -815.91 | |||||
| ROCE % | -54.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 9.92 | |||||
| Price-to-Free-Cash-Flow | 407 | |||||
| Price-to-Operating-Cash-Flow | 29.06 | |||||
| EV-to-EBIT | -6.89 | |||||
| EV-to-EBITDA | -9.76 | |||||
| EV-to-FCF | 202.58 | |||||
| Earnings Yield (Greenblatt) % | -14.56 | |||||
| FCF Yield % | 0.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaLundensis AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.103 | ||
| Beta | 0.14 | ||
| Volatility % | 100.85 | ||
| 14-Day RSI | 46.93 | ||
| 14-Day ATR (kr) | 0.040857 | ||
| 20-Day SMA (kr) | 0.42385 | ||
| 12-1 Month Momentum % | 46.34 | ||
| 52-Week Range (kr) | 0.28 - 1.4 | ||
| Shares Outstanding (Mil) | 50.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaLundensis AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaLundensis AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
PharmaLundensis AB Frequently Asked Questions
What is PharmaLundensis AB(XSAT:PHAL)'s stock price today?
The current price of XSAT:PHAL is kr0.41. The 52 week high of XSAT:PHAL is kr1.40 and 52 week low is kr0.28.
When is next earnings date of PharmaLundensis AB(XSAT:PHAL)?
The next earnings date of PharmaLundensis AB(XSAT:PHAL) is 2025-02-20.
Does PharmaLundensis AB(XSAT:PHAL) pay dividends? If so, how much?
PharmaLundensis AB(XSAT:PHAL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers